IbisVision

About:

IbisVision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma.

Website: https://www.ibisvision.co.uk/

Twitter/X: ibisvision

Top Investors: Deepbridge Capital, Scottish Enterprise, SBRI Healthcare, Apollo Informal Investment, Compiler Venture Capital

Description:

Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.

Total Funding Amount:

4.56M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Newhouse, North Lanarkshire, United Kingdom

Founded Date:

2013-01-01

Contact Email:

info(AT)mysite.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2023-05-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai